Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 24
8-K
Departure of Directors or Certain Officers
13 Jun 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
14 May 24
EFFECT
Notice of effectiveness
7 May 24
S-3
Shelf registration
30 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
424B5
Prospectus supplement for primary offering
15 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
8-K
Other Events
28 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
8-K
Other Events
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
9 Nov 23
8-K
Other Events
3 Nov 23
8-K
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
5 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
14 Aug 23
8-K
Departure of Directors or Certain Officers
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
8-K
Regulation FD Disclosure
25 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
8-K
Departure of Directors or Certain Officers
3 Apr 23
S-8
Registration of securities for employees
2 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
2 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
Latest ownership filings
4
Yuan Xu
17 Jun 24
4
Sara Bonstein
17 Jun 24
4
ROBERT W. ROSS
17 Jun 24
4
Christina Rossi
17 Jun 24
4
Paul J Clancy
17 Jun 24
4
Daniel J. Curran
17 Jun 24
4
James Samuel Shannon
17 Jun 24
3
James Samuel Shannon
17 Jun 24
4
Aoife Brennan
17 Jun 24
3
Aoife Brennan
17 Jun 24
4
Katarina Luptakova
3 May 24
4
Kevin M. Brennan
3 May 24
4
Christopher James Frankenfield
3 May 24
4
Rene Russo
3 May 24
SC 13G
GILEAD SCIENCES, INC.
5 Apr 24
SC 13G/A
Rock Springs Capital Management LP
5 Apr 24
4
Change in insider ownership
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
SC 13G
Rock Springs Capital Management LP
14 Feb 24
4
Change in insider ownership
9 Feb 24
SC 13G/A
Octagon Capital Advisors LP
6 Feb 24
SC 13G/A
Octagon Capital Advisors LP
5 Feb 24
4
Change in insider ownership
16 Jan 24
4
Christopher James Frankenfield
3 Jan 24
4
Katarina Luptakova
3 Jan 24
4
Kevin M. Brennan
3 Jan 24
4
Rene Russo
3 Jan 24
4
Katarina Luptakova
7 Sep 23
3
Katarina Luptakova
7 Sep 23
4
Rene Russo
18 Aug 23
4
Christopher James Frankenfield
18 Aug 23
4
Kevin M. Brennan
18 Aug 23
4
Martin H. Jr. Huber
18 Aug 23
4
Christopher James Frankenfield
7 Aug 23
3
Christopher James Frankenfield
7 Aug 23
4
ROBERT W. ROSS
13 Jun 23
4
Tomas J. Heyman
13 Jun 23
4
Yuan Xu
13 Jun 23
4
Sara Bonstein
13 Jun 23
4
Christina Rossi
13 Jun 23